Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(40.0%)
Phase 2
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 1(2)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04307576Phase 3Recruiting

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Role: collaborator

NCT03333187Phase 2Active Not Recruiting

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

Role: collaborator

NCT04177602Phase 1Terminated

Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial

Role: collaborator

NCT04895449Phase 1Completed

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19

Role: collaborator

NCT04971005Phase 2Terminated

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Role: collaborator

All 5 trials loaded